Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors

References

• Global Cancer Observatory. Cancer today. Lyon: International Agency for Research on Cancer; 2022. https://gco.iarc.fr/
   Google Scholar
• Zhang J, Chen P, Duan Y, Xiong H, Li H, Zeng Y, Liang G, Tang Q, Wu D. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment. Eur J Med Chem. 2021;215:113273.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L, et al. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur J Med Chem. 2016;108:495–504.
   PubMed Web of Science ®Google Scholar
• Xu H, Wang M, Wu F, Zhuo L, Huang W, She N. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorg Med Chem. 2020;28(12):115555.
   PubMed Web of Science ®Google Scholar
• Qiang H, Gu W, Huang DD, Shi W, Qiu Q, Dai Y, Huang W, Qian H. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2. Bioorg Med Chem. 2016;24(16):3353–3358.
   PubMed Web of Science ®Google Scholar
• Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P. Discovery of novel 4-(2-fluorophenoxy) quinoline derivatives bearing 4-oxo-1, 4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2013;21(11):2843–2855.
   PubMed Web of Science ®Google Scholar
• Gu W, Dai Y, Qiang H, Shi W, Liao C, Zhao F, Huang W, Qian H. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg Chem. 2017;72:116–122.
   PubMed Web of Science ®Google Scholar
• Hassan A, Badr M, Abdelhamid D, Hassan HA, Abourehab MAS, Abuo‐Rahma GEDA. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold. Bioorg Chem. 2022;120:105631.
   PubMed Web of Science ®Google Scholar
• Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clin Cancer Res. 2017;23(22):7034–7046.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci. 2009;30(12):624–630.
   PubMed Web of Science ®Google Scholar
• Poletto V, Rosti V, Biggiogera M, Guerra G, Moccia F, Porta C. The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: a speculative review. Crit Rev Oncol Hematol. 2018;132:89–99.
   PubMed Web of Science ®Google Scholar
• Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW, Mercurio AM. P-Rex1 promotes resistance to VEGF/VEGFR-targeted therapy in prostate cancer. Cell Rep. 2016;14(9):2193–2208.
   PubMed Web of Science ®Google Scholar
• Daudigeos-Dubus E, Le Dret L, Bawa O, Opolon P, Vievard A, Villa I, Bosq J, Vassal G, Geoerger B. Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. Int J Oncol. 2017;50(1):203–211.
   PubMed Web of Science ®Google Scholar
• Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19(4):512–526.
   PubMed Web of Science ®Google Scholar
• Negri FV, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C, Poggi G, Missale G, Fanello S, Salvagni S, et al. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int. 2015;35(8):2001–2008.
   PubMed Web of Science ®Google Scholar
• Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, et al. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res. 2017;23(18):5489–5501.
   PubMed Web of Science ®Google Scholar
• Liang J-w, Li S-l, Wang S, Li W-q, Meng F-h. Synthesis and biological evaluation of novel (E)-N′-benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening. J Enzyme Inhib Med Chem. 2020;35(1):468–477.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zheng P, Zhu W. Research progress of small molecule VEGFR/c-Met inhibitors as anticancer agents (2016–present). Molecules. 2020;25(11):2666.
   PubMed Web of Science ®Google Scholar
• Shi L, Wu T-T, Wang Z, Xue J-Y, Xu Y-G. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2. Bioorg Med Chem. 2014;22(17):4735–4744.
   PubMed Web of Science ®Google Scholar
• Ibrahim HA, Awadallah FM, Refaat HM, Amin KM. Design, synthesis and molecular modeling study for some new 2-substituted benzimidazoles as dual inhibitors for VEGFR-2 and c-Met. Future Med Chem. 2018;10(5):493–509.
   PubMed Web of Science ®Google Scholar
• Li C, Shan Y, Sun Y, Si R, Liang L, Pan X, Wang B, Zhang J. Discovery of novel anti-angiogenesis agents. Part 7: multitarget inhibitors of VEGFR-2, TIE-2 and EphB4. Eur J Med Chem. 2017;141:506–518.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai J, Lan X, Zhao Y, Yang F, Zhang H, Tang S, Liang G, Wang X, Tang Q, et al. Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in vitro and in vivo. Eur J Med Chem. 2022;233:114215.
   PubMed Web of Science ®Google Scholar
• Li S, Huang Q, Liu Y, Zhang X, Liu S, He C, Gong P. Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. Eur J Med Chem. 2013;64:62–73.
   PubMed Web of Science ®Google Scholar
• Martorana A, Monica GL, Lauria A. Quinoline-based molecules targeting c-Met, EGF, and VEGF receptors and the proteins involved in related carcinogenic pathways. Molecules. 2020;25(18):4279.
   PubMed Web of Science ®Google Scholar
• Nan X, Li H-J, Fang S-B, Li Q-Y, Wu Y-C. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions. Eur J Med Chem. 2020;193:112241.
   PubMed Web of Science ®Google Scholar
• Qi B, Tao H, Wu D, Bai J, Shi Y, Gong P. Synthesis and biological evaluation of 4‐phenoxy‐6,7‐disubstituted quinolines possessing semicarbazone scaffolds as selective c‐Met inhibitors. Arch Pharm Chem Life Sci. 2013;346(8):596–609.
   PubMed Web of Science ®Google Scholar
• Liao W, Hu G, Guo Z, Sun D, Zhang L, Bu Y, Li Y, Liu Y, Gong P. Design and biological evaluation of novel 4-(2-fluorophenoxy) quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2015;23(15):4410–4422.
   PubMed Web of Science ®Google Scholar
• Tang Q, Zhao Y, Du X, Chong L, Gong P, Guo C. Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Eur J Med Chem. 2013;69:77–89.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liao H, Liu M, Feng G, Fu B, Li R, Cheng M, Zhao Y, Gong P. Discovery and biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2014;22(22):6438–6452.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liao H, He C, Dou Y, Jiang M, Ren L, Zhao Y, Gong P. Design, synthesis and structure–activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents. Eur J Med Chem. 2014;83:581–593.
   PubMed Web of Science ®Google Scholar
• Liu M, Hou Y, Yin W, Zhou S, Qian P, Guo Z, Xu L, Zhao Y. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy) quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors. Eur J Med Chem. 2016;119:96–108.
   PubMed Web of Science ®Google Scholar
• Wang M, Xu S, Lei H, Wang C, Xiao Z, Jia S, Zhi J, Zheng P, Zhu W. Design, synthesis and antitumor activity of novel sorafenib derivatives bearing pyrazole scaffold. Bioorg Med Chem. 2017;25(20):5754–5763.
   PubMed Web of Science ®Google Scholar
• Zeidan MA, Mostafa AS, Gomaa RM, Abou-Zeid LA, El-Mesery M, El-Sayed MA-A, Selim KB. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur J Med Chem. 2019;168:315–329.
   PubMed Web of Science ®Google Scholar
• Younes AMM, Taha MM, Abdel-Monsef A-BH. (2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-acetic acid hydrazide: synthesis and reactions. J Asian Sci Res. 2013;3(8):800–809.
   Google Scholar
• El Kayal WM, Shtrygol SY, Zalevskyi SV, Shark AA, Tsyvunin VV, Kovalenko SM, Bunyatyan ND, Perekhoda LO, Severina HI, Georgiyants VA. Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide. Eur J Med Chem. 2019;180:134–142.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 37143654; 2022. https://pubchem.ncbi.nlm.nih.gov/compound/37143654
   Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 4975215; 2022. https://pubchem.ncbi.nlm.nih.gov/compound/4975215
   Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 4906019; 2022. https://pubchem.ncbi.nlm.nih.gov/compound/4906019
   Google Scholar
• Rivero IA, Somanathan R, Hellberg LH. Synthesis of 3-dipeptidyl-2,4(1H,3H)-quinazolinediones as potential anti-hypertensive agents. Synth Commun. 1998;28(11):2077–2086.
   Web of Science ®Google Scholar
• Mata A, Weigl U, Flögel O, Baur P, Hone CA, Kappe CO. Acyl azide generation and amide bond formation in continuous-flow for the synthesis of peptides. React Chem Eng. 2020;5(4):645–650.
   Web of Science ®Google Scholar
• Palla G, Predieri G, Domiano P, Vignali C, Turner W. Conformational behaviour and E/Z isomerization of N-acyl and N-aroylhydrazones. Tetrahedron. 1986;42(13):3649–3654.
   Web of Science ®Google Scholar
• Syakaev VV, Podyachev SN, Buzykin BI, Latypov SK, Habicher WD, Konovalov AI. NMR study of conformation and isomerization of aryl- and heteroarylaldehyde 4-tert-butylphenoxyacetylhydrazones. J Mol Struct. 2006;788(1–3):55–62.
   Web of Science ®Google Scholar
• Korcz M, Sączewski F, Bednarski PJ, Kornicka A. Synthesis, structure, chemical stability, and in vitro cytotoxic properties of novel quinoline-3-carbaldehyde hydrazones bearing a 1,2,4-triazole or benzotriazole moiety. Molecules. 2018;23(6):1497.
   PubMed Web of Science ®Google Scholar
• Lacerda RB, da Silva LL, de Lima CKF, Miguez E, Miranda ALP, Laufer SA, Barreiro EJ, Fraga CAM. Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production. PLOS One. 2012;7(10):e46925.
   PubMed Web of Science ®Google Scholar
• Lopes AB, Miguez E, Kümmerle AE, Rumjanek VM, Fraga CAM, Barreiro EJ. Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives. Molecules. 2013;18(10):11683–11704.
   PubMed Web of Science ®Google Scholar
• Uygun Y, Bayrak H, Özkan H. Synthesis and biological activities of methylenebis-4H-1,2,4-triazole derivatives. Turk J Chem. 2013;37(5):812–824.
   Web of Science ®Google Scholar
• Huan LC, Phuong CV, Truc LC, Thanh VN, Pham-The H, Huong L-T-T, Thuan NT, Park EJ, Ji AY, Kang JS, et al. (E)-N′-arylidene-2-(4-oxoquinazolin-4(3H)-yl) acetohydrazides: synthesis and evaluation of antitumor cytotoxicity and caspase activation activity. J Enzyme Inhib Med Chem. 2019;34(1):465–478.
   PubMed Web of Science ®Google Scholar
• Aboelmagd A, Salem EMS, Ali IAI, Gomaab MS. Synthesis of quinazolindionyl amino acid and hydrazone derivatives as possible antitumour agents. Org Chem. 2018;2018(3):20–35.
   Google Scholar
• Aboelmagd A, Salem EMS, Ali IAI, Gomaab MS. Synthesis of quinazolindionyl amino acid and dipeptide derivatives as possible antitumour agents. Org Chem. 2019;2019(5).
   Google Scholar
• Kuodis Z, Rutavičius A, Matijoška A, Eicher-Lorka O. Synthesis and isomerism of hydrazones of 2-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-ylthio) acetohydrazide. Open Chem. 2007;5(4):996–1006.
   Google Scholar
• Tumosienė I, Jonuškienė I, Kantminienė K, Mickevičius V, Petrikaitė V. Novel N-substituted amino acid hydrazone-isatin derivatives: synthesis, antioxidant activity, and anticancer activity in 2D and 3D models in vitro. Int J Mol Sci. 2021;22(15):7799.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Balwani S, Mathur D, Malhotra S, Singh BK, Prasad AK, Len C, Van der Eycken EV, Ghosh B, Richards NGJ, et al. Synthesis and anti-inflammatory activity evaluation of novel triazolyl-isatin hybrids. J Enzyme Inhib Med Chem. 2016;31(6):1520–1526.
   PubMed Web of Science ®Google Scholar
• Huang D, Yang J, Zhang Q, Wang G, Zhang Z, Zhang Y, Li J. Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors. Eur J Med Chem. 2021;223:113648.
   PubMed Web of Science ®Google Scholar
• Seliem IA, Panda SS, Girgis AS, Tran QL, Said MF, Bekheit MS, Abdelnaser A, Nasr S, Fayad W, Soliman AAF, et al. Development of isatin-based Schiff bases targeting VEGFR-2 inhibition: synthesis, characterization, antiproliferative properties, and QSAR studies. ChemMedChem. 2022;17(13):e202200164.
   PubMed Web of Science ®Google Scholar
• Hassan A, Badr M, Hassan HA, Abdelhamid D, Abuo‐Rahma GEDA. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Bioorg Med Chem. 2021;40:116168.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model. 2014;54(12):3284–3301.
   PubMed Web of Science ®Google Scholar
• Daina A, Zoete V. A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–1121.
   PubMed Web of Science ®Google Scholar